ライフサイエンスコーパス: country

1 an follow-up of 17.0 months in 966 sites (52 countries).

2 e included 358 studies (834 544 PLWH from 87 countries).

3 nce 2010 and focussing on the UK as the host country.

4 rica to estimate the risk of importation per country.

5 and the more populated southern parts of the country.

6 , sex, body mass index, type 2 diabetes, and country.

7 es (U5MRs) for each ethnic group within each country.

8 0 million traffic stops conducted across the country.

9 that correlate with subsistence strategy and country.

10 elines, but dose prescribed varies highly by country.

11 ty, which is unevenly distributed across the country.

12 strains predominating in each region of the country.

13 ft from red to white meat consumption in the country.

14 n and has been expanded to cities around the country.

15 pleted treatment and 1 (7%) moved out of the country.

16 f all febrile children attending EDs in that country.

17 d Kingdom, but increases are seen across the country.

18 perating with distant centers throughout the country.

19 s were similar between men and women in most countries.

20 e differs between low-income and high-income countries.

21 2-23 months was 84% (79-89) in low-mortality countries.

22 in primary school children in eight European countries.

23 rdiovascular organ support at 121 sites in 8 countries.

24 ) across upper-middle-income and high-income countries.

25 m 35 academic and community hospitals in ten countries.

26 high burden in low-income and middle-income countries.

27 ut across social contexts among MSM in the 9 countries.

28 tients were recruited from 389 centres in 39 countries.

29 nic obstructive pulmonary disease in the two countries.

30 he use of dental care by older adults in all countries.

31 ality of laboratory testing may vary between countries.

32 y and as many as one in eight in high-income countries.

33 he Netherlands, and Denmark as most affected countries.

34 ne at 36 hospitals in nine northern European countries.

35 commercial importance in Asian and European countries.

36 l laboratories or laboratories in developing countries.

37 emerging countries and fossil-fuel-dependent countries.

38 elative risks of all-cause mortality for 168 countries.

39 ge to work in institutions in four different countries.

40 particularly in low-income and middle-income countries.

41 e-control studies carried out in high-income countries.

42 m rural areas or low- or lower-middle-income countries.

43 tudy (n = 209) was recruited from 3 European countries.

44 1%, but estimates are higher in high-income countries.

45 o rural populations from less industrialized countries.

46 cases and deaths compared with higher income countries.

47 e of enteric fever at 6 study hospitals in 3 countries.

48 analyzing COVID-19 virus spread in different countries.

49 of major drivers of stunting decline between countries.

50 dern method of contraception increased in 37 countries.

51 vestigators, study design, institutions, and countries.

52 nity hospitals, and cancer centres across 25 countries.

53 the world's poorest households in low-income countries.

54 compared with some other seriously affected countries.

55 rol rates are poor in low- and middle-income countries.

56 plementation has recently begun in 3 African countries.

57 ividuals was effectively reduced in multiple countries.

58 e disease is still a challenge in developing countries.

59 ts and in low-income and lower middle-income countries.

60 sticide-attributable suicides across several countries.

61 oid conjugate vaccine (TCV) are ongoing in 4 countries.

62 s heterogeneity in these associations across countries.

63 mmended by health authorities in a number of countries.

64 is a priority in many low- and middle-income countries.

65 or elimination protocols in resource-limited countries.

66 r depression in low-income and middle-income countries.

67 nificant morbidity and mortality in affected countries.

68 r health, well-being, and economies of these countries.

69 American VREfm recovered from 1998-2015 in 5 countries.

70 lar causes in low-, middle-, and high-income countries.

71 ng 12% of the total population in low-income countries.

72 ng worldwide and particularly in high-income countries.

73 agnosis of blastomycosis in resource-limited countries.

74 bance accounting for >75% of the losses in 7 countries.

75 label, phase 3 trial done at 196 sites in 21 countries.

76 s very heterogeneous both between and within countries.

77 9, CC398 and CC8 were only found in specific countries.

78 VID-19) epidemic has spread from China to 25 countries.

79 tinational study (n = 4,098 participants, 19 countries, 13 languages), adjusting only for current and

80 p median 17.9% [12.3-20.5]) than high-income countries (14.1% [6.6-17.8]).

81 reterm births in 19 regions from 11 European countries, 2011-2012), we included 607 women with a sing

82 cts who participated in the study across the country, 269 (7.6%) satisfied the diagnostic criteria fo

83 the underlying levels of transmission across countries(3).

84 o 59% in Black women), and between different countries (44-47% in Uganda and Zambia vs 36% in Nigeria

85 Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% were recei

86 mpact for Italy, Greece, and Spain, as these countries account for around 95% of the European olive o

87 Five countries accounted for 50% of all 14.8 million children

88 We compared this with scenarios in which countries achieve 90% TB incidence reductions between 20

89 eries from 7,538 temperature sensors from 51 countries across all key biomes.

90 controlled study was done at 118 sites in 13 countries across Asia, Europe, and North America.

91 overweight and/or obesity prevalence in the country, adjusted for cluster and sample weight.

92 In nearly all countries, adjustment for wealth, education, and place o

93 of transmission have already occurred in 12 countries after case importation.

94 ders with a prevalence of 3-16% depending on country, age and sex.

95 cancer were more than 20 per 100 000 in six countries, all in southern Africa and eastern Africa.

96 3) across low-income and lower-middle-income countries and $237 per HLYG (95% UI 191-303) across uppe

97 combine standardized achievement data for 58 countries and 12,000 US school districts with detailed w

98 two population-based samples from different countries and age ranges.

99 In both countries and at all ages, there was a clear gradient to

100 ncy of results across a variety of different countries and cultures in two of the most commonly used

101 ncorporates data from low- and middle-income countries and existing studies lack a description of the

102 vements are especially important in emerging countries and fossil-fuel-dependent countries.

103 dividual economic sectors, comparable across countries and geographies.

104 hal gynecologic malignancy in industrialized countries and has limited treatment options.

105 income countries (LMICs) than in high-income countries and is rising.

106 g and HFOV were more common in middle-income countries and less frequently used in North America.

107 ions might be more applicable to high-income countries and might not be generalisable because of regi

108 en reported from over 160 fish species in 20 countries and notably, this is the first non-salmonid di

109 ata from the Human Mortality Database for 49 countries and regions with emphasis on the long time ser

110 achRefPop) located across different European countries and sharing the same experimental design.

111 c cervical cancer 5-year net survival in 200 countries and territories.

112 mortality rates in the US vs that of 18 OECD countries and the timing of any increases in excess mort

113 d patients from 26 hospitals in six European countries and the USA.

114 representative samples, we find that person-country and person-region value congruence predict six w

115 The first-round included 137 parents (eight countries) and 245 surgeons (10 countries), the second-r

116 bei province, other Chinese provinces, other countries) and interventions.

117 cords are sparse, especially from developing countries, and are frequently inaccurate throughout much

118 care worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening sy

119 tember, 2015, and December, 2019, across 149 countries, and including 284 381 individuals.

120 en of DR screening in low- and middle-income countries, and these results will allow for a better sel

121 es; demand for contraception increased in 42 countries, and use of a modern method of contraception i

122 a wise use of resources, even in high-income countries; and that screening has substantial opportunit

123 Urban populations from highly industrialized countries are characterized by a lower gut bacterial div

124 While countries are increasingly making efforts to reduce pove

125 require countries to fulfil their promises; countries are left to choose their conditional and uncon

126 vir, large-scale studies in resource-limited countries are now possible.

127 many areas of the world, and particularly in countries around the Mediterranean basin.

128 cipants who were current residents of an SSA country, at least 50% of whom were aged between 15 and 6

129 f NPIs for several European and non-European countries between January and the end of May 2020.

130 ed with lower food insecurity in high-income countries but corresponded to increased food insecurity

131 Improving diets is affordable in many countries but for many people would require some combina

132 Results were similar by country but varied by age group.

133 ice coverage makes little difference in some countries, but reduces it by more than 10% in others.

134 repository in every nuclear waste-generating country, but carbonate rocks may serve as a potential al

135 diagram of how civil wars in low-governance countries can have both positive and negative impacts on

136 The modelled cohort matched that of a two-country clinical trial.

137 , thereby bringing genomic medicine in these countries closer to clinical fruition.

138 y individual surveyors spread throughout the country, constituting a sophisticated network of "people

139 World region, country; countries' economic, social, and health system

140 ted at 74 intensive care units in 8 European countries (December 2015-December 2017) that included 30

141 edictive probability maps that can inform in-country decision makers of the likelihood that their eli

142 r time in 43 countries, with increases in 30 countries; demand for contraception increased in 42 coun

143 e, online survey conducted in eight European countries, developed by eight representatives of patient

144 lity clinical care outcome and indicators of country development (gross domestic product [GDP] per ca

145 There are large inter-country differences in the burden of kidney cancer and i

146 thers and base their decisions on what other countries do.

147 World region, country; countries' economic, social, and health system character

148 When countries engineer the climate, conflict can arise becau

149 and p=0.40 for France), and for all assessed countries except France using ASCO-VF (p=0.56 for the US

150 pe) globally (69.0% versus 31.0%) and in all countries except South Africa.

151 Across all countries, financial constraints were identified as the

152 however, value type moderates whether person-country fit is positively or negatively associated with

153 rojected for 73 low-income and middle-income countries for each of the three scenarios for both 4-wee

154 of countries for males and 47.8% (76/159) of countries for females where population ageing was associ

155 whole world, as well as in 55.3% (84/152) of countries for males and 47.8% (76/159) of countries for

156 e been authorized for introduction across 18 countries for the classical biological control of weeds.

157 All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were inclu

158 id epidemiological data in early introducing countries has reinforced the need for continued evidence

159 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and

160 Several countries have notably reduced childhood stunting relati

161 Many European countries have responded to the COVID-19 pandemic by imp

162 Pharmacies across the country have been incorporating CLIA-waived point-of-car

163 insecticidal nets (LLINs)(5), with many SSA countries having planned campaigns for 2020.

164 Countries' health expenditures include paying for genera

165 s of HIV are in low-income and middle-income countries, high-quality epidemiological data for haemato

166 cording to region, level of development, and country HIV prevalence.

167 In both high- and low-income countries, HIV-negative children born to HIV-positive mo

168 enrolling 800 pregnant women in each of four countries (i.e., Peru, Guatemala, Rwanda, and India).

169 e of HBV infection of 2% or greater, such as countries in Africa and Asia, the Pacific Islands, and p

170 -three pollen monitoring stations from three countries in Europe and for 3 years (2014-2016) were use

171 wild birds and spread via bird migration to countries in Europe, Africa, and North America.

172 t 675 academic and community hospitals in 22 countries in North America, Europe, South America, Asia,

173 rates of this disease have increased in many countries in recent decades.

174 living with HIV are especially important for countries in southern Africa and eastern Africa, where a

175 UNAIDS has prioritised Malawi and 21 other countries in sub-Saharan Africa for fast-tracking the en

176 We analysed data from 16 countries in sub-Saharan Africa where at least one Demog

177 herapies have shown reduced efficacy in some countries in the GMS at some point.

178 ction for other low-income and middle-income countries in the region.

179 The prevalence of FH is unknown in 90% of countries in the world.

180 irus 2 (SARS-CoV-2) has reached nearly every country in the world with extraordinary person-to-person

181 2008 classifications) from 74 centres in 13 countries (in Asia, Europe, North America, and South Ame

182 over the last several decades in high-income countries, in circumstances when delays in timely delive

183 y-specific level and aggregated according to country income group and the proportion of suicides due

184 lth Organization recommendations and planned country introductions.

185 Wider molecular surveillance in surrounding countries is required.

186 ty has become a global pandemic in developed countries, leading to a host of medical conditions that

187 We used linear regression to examine country-level associations between the gender developmen

188 goal would require equitable translation to country-level contributions.

189 76 per 100 women), compared with high-income countries like the United States (1.69 per 100 women).

190 expanding rapidly in low- and middle-income countries (LMIC).

191 Examples of successful high-income countries-LMIC partnerships are provided.

192 ke is higher in low-income and middle-income countries (LMICs) than in high-income countries and is r

193 ave been conducted in low- and middle-income countries (LMICs), especially in South America.

194 CR programs in many countries may need to increase their dose, which could b

195 os of flat TB incidence trends in individual countries.Measurements and Main Results: We estimated TB

196 limate, conflict can arise because different countries might prefer different temperatures.

197 In some African countries, more than one-half of 45- to 49-y-old mothers

198 As cardiovascular disease decreases in many countries, mortality from cancer will probably become th

199 Countries must strengthen immunization programs to achie

200 HF), the leading cause of death in developed countries, occurs in the setting of reduced (HFrEF) or p

201 e, and compares it with the situation in the countries of the European boreal biogeographic region.

202 Attrition was associated significantly with country of birth, language spoken at home, and marital s

203 justed for potential confounders (age, race, country of birth, total people per household, US region,

204 trol and Prevention and Gilead Sciences, the country of Georgia embarked on the world's first hepatit

205 le size, displacement duration, visa status, country of origin, current residence, type of interview

206 Our findings from 34 countries on six continents suggest that survival is hig

207 r acute heart failure from 358 centres in 44 countries on six continents.

208 er in populations living in northern African countries or South Africa compared with sub-Saharan Afri

209 atch with those of people living in the same country or region.

210 ualitative studies were identified from five countries over 26 years.

211 edictor of a country's UHC index score, some countries perform better than others in the same income

212 he lowest estimation, and with GDP and total country population as model predictors, the financial bu

213 n this study, we observed that indicators of country preparedness to deal with CVDRFs are poor proxie

214 Accordingly, health authorities in some countries prioritize vaccination of this population.

215 inuously increasing numbers of participating countries, publications, and scientists.

216 In low-income countries, reduction of transmission is of paramount imp

217 chieved in many low-income and middle-income countries, reductions in stillbirth and neonatal mortali

218 Although their countries' responses to the COVID-19 pandemic differed r

219 challenge in Brazil despite expansion of the country's internationally recognized Family Health Strat

220 ld allow a more standardized assessment of a country's surgical system.

221 We examined the association between a country's trade policy score and the probability of indi

222 h per-capita income is a good predictor of a country's UHC index score, some countries perform better

223 al survival varies by country, so the single country setting is a limitation.

224 Countries should consider incorporating dual HIV and syp

225 e future of the virus is unknown at present, countries should continue to share their experiences, sh

226 In this phase of the pandemic many countries showed an almost linear growth of confirmed ca

227 Functional survival varies by country, so the single country setting is a limitation.

228 The analysis involved 14 countries spanning low-income to high-income settings, a

229 understand overall trends rather than guide country-specific allocation.

230 wealth quintiles and age groups and present country-specific estimates.

231 st-effectiveness ratios were analysed at the country-specific level and aggregated according to count

232 p did not have the lowest U5MR in any of the countries studied.

233 re identified in more than two-thirds of the countries studied.

234 ings from existing literature and 5 exemplar country studies (Nepal, Ethiopia, Peru, Kyrgyz Republic,

235 Some very low death rate countries such as Eastern Asia, Central Europe, or the B

236 majority of the submitted samples in various countries suggests a possible fitness gain conferred by

237 Compared with other countries, Taiwan has had relatively few cases during th

238 Low-income countries tended to have higher prevented fractions (gro

239 ct of population ageing on mortality for 195 countries/territories and 169 causes of death.

240 ices use is more prevalent (~7.8%) in "free" countries than in either "partially free" (~6.7%) or "no

241 , 178,100-231,000) more people died in these countries than would have had the pandemic not occurred.

242 opportunity costs in low- and middle-income countries that offset its hypothesized benefits.

243 We identified three clusters of countries that share the same exposure to the risk origi

244 ing RRT in the Flanders region of Belgium, a country that has been severely affected by coronavirus d

245 portation policies in communities across the country that incorporate consistent implementation evalu

246 rents (eight countries) and 245 surgeons (10 countries), the second-round response rates were 61% and

247 As transmission intensifies in other countries, the interplay between age, contact patterns,

248 Across 29 countries, the present research investigated whether wel

249 and reached academic institutions across the country, the authors reflect on lessons learned that may

250 are services in selected settings across the country; the effectiveness and sustainability of these p

251 Trachoma disappeared from high income countries through enhancements of hygiene and sanitation

252 pists with a wide range of experience from 4 countries to benchmark CAD system performance.

253 te underwater video surveys undertaken in 36 countries to construct an empirically supported individu

254 study data from 46 geographical sites in 13 countries to estimate dengue force of infection (FOI, th

255 el indicators of social determinants from 74 countries to examine change in satisfaction of contracep

256 central enforcing authority and only require countries to fulfil their promises; countries are left t

257 ater content from 2-year experiments in each country to assess their ability to simulate observed yie

258 ere enrolled at seven community sites in six countries (two sites in India and one site each in the D

259 rs have experienced a child die, yet in many countries, up to one-third have.

260 2012 were assessed in 44 populations from 41 countries using the Cancer in Five Continents plus datab

261 tumours and clinical benefit in all assessed countries, using the ESMO-MCBS (p=0.16 for the USA, p=0.

262 We did not account for within-country variation in vaccine coverage, and the optimisat

263 Within-country variations in health status are often not examin

264 adjusted for the stratification variable and country) was assessed for non-inferiority (HR limit 1.3)

265 udy done in 48 acute care hospitals in eight countries, we enrolled patients with acute ischaemic str

266 l supply data and 1,879 life tables from 103 countries, we test for these effects at a macrolevel: be

267 c urothelial carcinoma, from 221 sites in 35 countries, were randomly assigned to receive atezolizuma

268 pollution, especially in cities in developed countries where air pollution is caused predominantly by

269 Most patients had traveled to countries where brucellosis is endemic and presented wit

270 strategy to increase micronutrient intakein countries where rice is a staple food.

271 tment, especially for patients in low-income countries where the clinical need is greatest, and does

272 ly evaluated in low-income and middle-income countries, where the disease is most common.

273 hat these effects are confined to developing countries, which are often dominated by small-holder far

274 than 5 years in low-income and middle-income countries who have compromised development.

275 nd highlight the need to consider harmonized country-wide public policies to control local HIV epidem

276 kidney cancer and it is generally higher in countries with a high SDI.

277 mplars," studies success factors among these countries with a lens toward replicability.

278 this kind only exist in a reduced number of countries with a limited activity.

279 While they are more abundant overall in countries with a low human development index, some count

280 Proportionally, countries with a low UNDP human development index (HDI)

281 rs) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism w

282 ies with a low human development index, some countries with high human development index are also hot

283 ly as forced displacement and migration from countries with high rates of this practice increases.

284 injury following vaginal birth were found in countries with higher rates of spontaneous birth (nullip

285 Most countries with large annual reductions in such mortality

286 y improve health and health equality even in countries with low iTFA intake.

287 y building should be urgently prioritised in countries with moderate risk that might be ill-prepared

288 Countries with rapid population and income growth greatl

289 Policies, especially in countries with stronger links between neighborhood and d

290 ich observed reduced severity of COVID-19 in countries with universal BCG vaccination policies.

291 ction-related hospitalisation in high-income countries with varying CS rates.

292 in antenatal care can be cost-saving across countries with varying HIV prevalence.

293 transplant activity in 6 centers from these countries with varying local COVID-19 caseload was also

294 Brazil is a megadiversity country with more tropical forest than any other, and is

295 f cases explains 66% of the variation across countries, with a resulting age-standardized median CFR

296 ive in the past year changed over time in 43 countries, with increases in 30 countries; demand for co

297 among adults without asthma from 11 European countries within a 20-year follow-up (ECRHS and SAPALDIA

298 cine procedures declined precipitously, with countries worldwide being affected by the pandemic to a

299 tural acceptance and legalization in several countries worldwide.

300 This shows that all countries would need to accelerate the implementation of